Company: WHWK
Filing Date: 2025-06-13
Form Type: 8-K
Source: 0001193125-25-140810
Chunk: 1

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-06-13
Form: 8-K
Item: Item 5.07
Chunk 1
---
 Class II directors at the Annual Meeting, the authorized number of directors of the board of directors of the Company was decreased from ten (10) directorships to nine (9) directorships, consisting of three Class I directorships, three Class II directorships, and three Class III directorships.

Proposal 2: To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table inthe “ Executive Compensation” section of the Proxy Statement.

         For        Against      Abstentions      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────
  18,855,748      4,692,033           14,168             5,128,059  

Proposal 3: Ratification of the appointment of BDO USA, P. C. as the Company’s independent registered public accounting firm for the fiscal year endingDecember 31, 2025.

         For      Against      Abstentions  
 ────────────────────────────────────────────
  28,065,323      524,039          100,646  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                     WHITEHAWK THERAPEUTICS, INC.  
  June 13, 2025      /s/ Scott Giacobello          
                     Scott Giacobello              
                     Chief Financial Officer